Verrica Pharmaceuticals Stock Price, News & Analysis

Verrica Pharmaceuticals (Nasdaq: VRCA) announced that President and CEO Ted White will present a business overview at the virtual 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 5:25 p.m. ET. The presentation will include insights into Verrica's dermatology therapeutics, especially their late-stage product candidates, VP-102 for treating molluscum and warts, and VP-103 for plantar warts. Additionally, Verrica has a global license agreement with Lytix Biopharma for developing LTX-315 for dermatologic oncology.

Verrica Pharmaceuticals (Nasdaq: VRCA) reported its first-quarter financial results for 2021, highlighting a significant expansion and preparation for the potential FDA approval of VP-102 for molluscum, with a PDUFA goal date set for June 23, 2021. The company raised $30 million through a public offering and recognized $12 million in license revenues from its agreement with Torii Pharmaceutical for VP-102's development in Japan. The net loss narrowed to $0.9 million from $9.8 million year-over-year, with cash equivalents of $87.7 million supporting operations through mid-2023.

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) will present a business overview at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 8:45 a.m. ET. CEO Ted White will lead the presentation, which highlights Verrica's focus on dermatology therapeutics. The company is advancing VP-102 for treating molluscum and warts, and VP-103 for plantar warts. Additionally, Verrica has partnered with Lytix Biopharma to develop LTX-315 for dermatologic oncology. A live webcast and replay will be available for those unable to attend the event.

Verrica Pharmaceuticals (NASDAQ: VRCA) announced that Dr. Gary Goldenberg has been elected as an active member of the American Dermatological Association (ADA), a prestigious recognition in dermatology. CEO Ted White praised Dr. Goldenberg for his contributions to the field. The ADA, founded in 1876, aims to improve dermatologic health care and is known for its influential role in dermatological education and research. Verrica focuses on developing treatments for skin diseases, including its late-stage candidate VP-102 for molluscum and warts, and has partnered with Lytix Biopharma to develop LTX-315 for dermatologic oncology.

Verrica Pharmaceuticals (NASDAQ: VRCA) announced a public offering of 2,033,899 shares at $14.75 each, aiming for gross proceeds of approximately $30 million. Underwriters have a 30-day option for an additional 305,084 shares. The offering is set to close around March 25, 2021, pending customary conditions. Jefferies, Cowen, and RBC Capital Markets are overseeing the offering. This follows a shelf registration declared effective in March 2020. The funds will support Verrica's dermatology product development, including treatments for skin diseases.

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced its intention to offer and sell shares of common stock in an underwritten public offering, subject to market conditions. The offering includes a 30-day option for underwriters to purchase an additional 15% of the shares. Jefferies LLC, Cowen and Company, and RBC Capital Markets are managing the offering. The shares will be sold under a shelf registration statement filed with the SEC. The actual size and terms of the offering are not guaranteed.

Verrica Pharmaceuticals (NASDAQ: VRCA) announced a License Agreement with Torii Pharmaceutical, granting exclusive rights to develop and commercialize its product candidates for molluscum contagiosum and common warts in Japan. Torii will make an upfront payment of $11.5 million and may pay up to $58 million based on milestones. The lead candidate, VP-102, is under FDA review, with a PDUFA goal date of June 23, 2021. The partnership aims to leverage Torii's expertise to address the unmet medical needs of approximately 1.6 million cases of molluscum in Japan.

Verrica Pharmaceuticals (Nasdaq: VRCA) announced the FDA's acceptance of its resubmitted NDA for VP-102, targeting molluscum contagiosum, with a PDUFA goal date of June 23, 2021. The company also revealed that Torii Pharmaceutical will develop and commercialize VP-102 in Japan, with a potential $69.5 million in milestone payments. During Q4 2020, Verrica reported a net loss of $13 million, an increase from $7.6 million in Q4 2019. Full-year 2020 losses reached $42.7 million. Research and development expenses decreased to $2.3 million in Q4 2020. As of December 31, 2020, cash reserves totaled $65.5 million.

Verrica Pharmaceuticals (Nasdaq: VRCA) announced that CEO Ted White will present a business overview at the H.C. Wainwright Annual Global Life Sciences Conference on March 9-10, 2021. A pre-recorded presentation will be available on-demand starting at 7:00 a.m. ET on March 9, 2021. The event can be accessed via a webcast link provided in the announcement and will also be available on the Verrica website. The company is focused on developing medications for skin diseases, including its late-stage product candidate VP-102, aimed at treating molluscum and warts.